What are the indications, recommended dosing, contraindications, and adverse effects of Diamox (acetazolamide)?

Diamox (Acetazolamide): Clinical Overview

Diamox (acetazolamide) is a carbonic anhydrase inhibitor with FDA-approved indications for glaucoma, epilepsy, edema, and acute mountain sickness, with emerging evidence supporting its use in idiopathic intracranial hypertension and central sleep apnea. 1

Mechanism of Action

Acetazolamide inhibits carbonic anhydrase, blocking the reversible reaction of carbon dioxide hydration and carbonic acid dehydration. This produces:

• Renal effects: Bicarbonate loss carrying sodium, water, and potassium, resulting in urinary alkalinization and diuresis
• CNS effects: Decreased cerebrospinal fluid production, reducing intracranial pressure
• Ocular effects: Reduced aqueous humor secretion, lowering intraocular pressure
• Respiratory effects: Metabolic acidosis stimulating ventilation 1

Primary Indications & Dosing

FDA-Approved Uses

Acute Mountain Sickness (Prevention)

• Dose: 250 mg every 8-12 hours OR 500 mg controlled-release once daily
• Start before ascent and continue during rapid altitude gain
• Reduces headache, nausea, shortness of breath, dizziness, and sleep difficulties 1

Glaucoma

• Reduces intraocular pressure through decreased aqueous humor production 1

Epilepsy

• Adjuvant therapy for certain seizure disorders 1

Edema

• Cardiac edema and abnormal fluid retention 1

Guideline-Supported Off-Label Uses

Idiopathic Intracranial Hypertension (IIH)

• Starting dose: 250-500 mg twice daily
• Target dose: Titrate upward; IIHTT trial used maximum 4 g/day (44% achieved this, majority tolerated 1 g/day)
• Important caveat: Acetazolamide has NOT been shown effective for headache treatment alone in IIH—it treats elevated intracranial pressure, not headache 2
• Note: Not all UK clinicians prescribe acetazolamide for IIH due to limited evidence and side effect profile 2

Central Sleep Apnea (Multiple Etiologies)

• Dose range: 250-1,000 mg daily
• AASM 2025 conditional recommendation for CSA due to:
  • Primary CSA
  • Heart failure
  • Medication/substance use
  • Treatment-emergent CSA
  • Medical conditions
  • High altitude 3
• Improves AHI (apnea-hypopnea index) and excessive sleepiness
• Critical monitoring: In heart failure patients, follow electrolytes after 2-4 weeks due to risk of acid-base disturbance and arrhythmias 3

Acute Decompensated Heart Failure

• Dose: 500 mg IV once daily added to loop diuretics
• The ADVOR trial (2022) showed 42.2% vs 30.5% successful decongestion with acetazolamide vs placebo (risk ratio 1.46, P<0.001) 4
• Best responders: Patients with serum bicarbonate ≥27 mmol/L and GFR >50 mL/min 5
• Acts as a "chloride-regaining diuretic" under the chloride theory of heart failure 6
• Recent evidence (2025) confirms improved diuretic efficiency and natriuresis 7

Contraindications (FDA Label)

Absolute contraindications 1:

• Depressed sodium and/or potassium serum levels
• Marked kidney disease or dysfunction
• Marked liver disease or dysfunction
• Suprarenal gland failure
• Hyperchloremic acidosis
• Cirrhosis (risk of hepatic encephalopathy)
• Chronic non-congestive angle-closure glaucoma (long-term use may mask worsening while permitting organic angle closure)
• Sulfonamide allergy (acetazolamide is a sulfonamide derivative; cross-reactivity can cause fatal anaphylaxis) 8

Renal dosing: Do not administer more frequently than every 12 hours if creatinine clearance <50 mL/min 9

Adverse Effects

Common Side Effects (Dose-Dependent)

Most frequent 2, 3:

• Paresthesias (hands/feet): Number needed to harm = 2.3 (most common; dose-dependent) 10
• Dysgeusia (altered taste): NNH = 18 (dose-dependent) 10
• Polyuria: NNH = 17 10
• Fatigue: NNH = 11 (trend toward dose-dependence) 10
• Diarrhea
• Nausea/vomiting
• Tinnitus
• Depression

Metabolic/Electrolyte Effects

• Hypokalemia (constant decrease throughout treatment) 6
• Metabolic acidosis
• Increased diuresis
• Blood urea nitrogen and creatinine elevation (short-term; typically returns to baseline long-term) 6

Rare but Serious

• Renal stones (rare) 2, 3
• Anaphylaxis (in sulfonamide-allergic patients) 8
• Arrhythmias (theoretical risk in heart failure due to electrolyte disturbances) 3

Quality of Evidence on Side Effects

A 2020 systematic review and meta-analysis (42 studies, N=1274) established low-to-moderate quality evidence for these risks, with clear dose-response relationships for paresthesias and dysgeusia 10.

Critical Clinical Pearls

Monitoring Requirements:

• Baseline and follow-up electrolytes (especially potassium, bicarbonate, chloride)
• Renal function (BUN, creatinine)
• In heart failure: cardiac function, AHI, sleep quality at 2-4 weeks 3

Drug Interactions:

• Highly protein-bound; primarily renal elimination 9
• Plasma half-life 4-8 hours, but pharmacologic effects last longer 9

Patient Selection for Heart Failure:

• Best candidates: Bicarbonate ≥27 mmol/L, GFR >50 mL/min 5
• Preserves plasma volume and renal function when used appropriately 6
• Chloride concentration increases within 10 days and persists ~60 days 6

Altitude Sickness Specifics:

• Patients with transient/mild CSA at altitude may reasonably decline treatment 3
• Definitive treatment for high-altitude CSA remains descent 3